Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the ...

Biocon's stock rises 1.22% as clinical data for Yesafili biosimilar is published, marking a key milestone for the company.

US President hints at steep pharmaceutical tariffs but offers 12–18 months of relief; Nifty Pharma and Healthcare indices ...

Read all the latest news headline updates on biocon stock. Get all the biocon stock breaking news updates, videos, photostories and more at Business Standard.

EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus 22% in the same ...

Solid earnings, robust biosimilars growth, and improving margins drive renewed optimism; analysts see double-digit upside ...

Viatris-owned Mylan is looking to sell part of its 5.64% stake in Biocon through a block deal in the next seven to eight days ...

Biocon Limited has announced the publication of two peer-reviewed clinical studies supporting the safety, efficacy and ...

The stock of Biocon saw a sharp rally in May, gaining nearly 20 per cent. But in June, it was largely sideways and even ...

Biocon said that its long-standing partner Duopharma Biotech has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over MYR 225 million this year.